Nonhormonal hope for vasomotor symptoms?

Article

Desvenlafaxine succinate, a serotonin norepinephrine reuptake inhibitor (SNRI), reduces hot flashes by about 64% after 3 months of use, according to the results of a double-blind, placebo-controlled trial.

Desvenlafaxine succinate, a serotonin norepinephrine reuptake inhibitor (SNRI), reduces hot flashes by about 64% after 3 months of use, according to the results of a double-blind, placebo-controlled trial.

Researchers randomized 707 healthy postmenopausal women experiencing 50 or more moderate-to-severe hot flushes per week to either desvenlafaxine 50, 100, 150, or 200 mg or placebo daily for 52 weeks.

Desvenlafaxine 100 mg/d significantly reduced the average daily number of hot flushes compared with placebo at weeks 4 (P=.013) and 12 (P=.005). In addition, compared with placebo, 12 weeks of 100 mg/d of the drug significantly reduced the severity of hot flushes and was associated with a significantly higher 75% responder rate (50% for desvenlafaxine vs. 29% for placebo). Efficacy, as measured by a 50% reduction from baseline in number of hot flushes, was reached within 1 week of treatment, compared with 3 to 4 weeks for placebo. And desvenlafaxine significantly reduced nighttime awakenings due to hot flushes.

Speroff L, Gass M, Constantine G, et al. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol. 2008;111: 77–87.

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Recent Videos
Neal Barnard, MD, FACC, highlights AMA's new breast cancer prevention guidelines | Image Credit: pcrm.org.
Zachary Wagner, PhD, discusses the harms of bias in reproductive care | Image Credit: ornsife.usc.edu.
Ciera Kirkpatrick, PhD, shows how TikTok is transforming cervical cancer awareness | Image Credit: linkedin.com.
Maria Gallo, PhD, discusses high attendance at crisis pregnancy centers | Image Credit: © x.com.
Related Content
© 2025 MJH Life Sciences

All rights reserved.